Access Statistics for Mary K. Olson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Pharmaceutical Expenditure and Regulatory Policy in the NHS 0 0 0 0 0 0 1 332
Total Working Papers 0 0 0 0 0 0 1 332


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Agency Rulemaking, Political Influences, Regulation, and Industry Compliance 0 0 0 0 1 1 1 361
Are novel drugs more risky for patients than less novel drugs? 0 0 0 29 2 7 10 120
Eliminating the U.S. drug lag: Implications for drug safety 0 0 0 13 1 1 2 109
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 1 7 0 2 5 58
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 0 2 0 1 6 21
Firm Characteristics and the Speed of FDA Approval 0 0 0 41 0 0 2 142
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? 0 0 1 3 0 0 3 29
Pharmaceutical Policy Change and the Safety of New Drugs 0 0 1 7 1 1 5 68
Political Influence and Regulatory Policy: The 1984 Drug Legislation 0 0 0 0 0 0 0 176
Reassessing the impact of health IT: Hidden costs and consequences of vendor heterogeneity 0 1 1 1 0 2 2 2
Regulatory Agency Discretion among Competing Industries: Inside the FDA 0 0 0 0 1 3 3 190
Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA 0 0 0 25 1 1 1 121
Substitution in Regulatory Agencies: FDA Enforcement Alternatives 0 0 0 0 0 0 0 200
The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D 0 0 0 12 0 0 1 70
The risk we bear: The effects of review speed and industry user fees on new drug safety 0 0 0 26 0 0 4 137
Total Journal Articles 0 1 4 166 7 19 45 1,804


Statistics updated 2025-08-05